Immune dysregulation and pharmacogenomics in neurodevelopmental disorders, part 2: a review of inflammation-induced phenoconversion
Medical Research Archives · 2026
DOI: 10.18103/mra.2026.0767 ↗Kurz gefasst
Fachartikel in der Zeitschrift Medical Research Archives, 2026. Verfasst von Jeffrey L. Clothier und 1 weiteren Autor:innen.
Abstract (Originalsprache)
Pharmacogenomic dosing translates cytochrome P450 genotype into a predicted metabolizer phenotype and treats it as a stable property of the patient. Phenoconversion — divergence of true metabolic capacity from genotype prediction — is well documented, occurring in roughly thirty percent of patients in studies of disease-related factors, and guidance already suggests correcting for enzyme-inhibiting co-medication. Inflammation produces the same shift through a separate, non-pharmacological route no dosing algorithm incorporates. This review, the second of three companion papers in the series Immune Dysregulation and Pharmacogenomics in Neurodevelopmental Disorders, argues that the omission matters most in neurodevelopmental disorder populations, where metabolic phenotype should be treated as a state variable rather than a fixed characteristic. The mechanism is transcriptional. Interleukin-6 suppresses drug-metabolizing enzymes and transporters broadly rather than by isoform, acting through MAPK and PI3K signaling and converging on the retinoid X receptor RXRα, whose silencing alone reproduces the inflammatory expression pattern. In patients, a systematic review spanning 218 studies finds the effect isoform-specific, disease-dependent, and reversible as inflammation resolves. Clozapine concentrations have risen more than threefold during pneumonia on an unchanged dose, returning to baseline as acute-phase proteins normalized. Two observations reframe the problem. Among sixteen patients with heart failure, seven were functional CYP2C19 poor metabolizers though none were so genotypically, at cytokine concentrations well below proposed acute thresholds — chronic low-grade inflammation, not acute illness, did the converting. And where genotype and inflammatory markers were measured together, they governed different metabolic branches rather than one shared capacity. We propose that the two immunophenotypes of the companion paper predict phenoconversion behavior: a developmentally fixed one implying a stable baseline assessable once, a dynamically maintained one implying a fluctuating baseline requiring reassessment. The dynamic half has empirical support; the constitutional half has none, and we state the asymmetry. We further show, through three syndromes, that the genotype half may itself depart from reference assumptions. The absence of inflammatory state from pharmacogenomic guidance appears architectural rather than accidental: the unit of analysis is a gene and a drug, and inflammatory state belongs to neither.
Zitieren
APA
Clothier, J. L., & Harville, T. O. (2026). Immune dysregulation and pharmacogenomics in neurodevelopmental disorders, part 2: a review of inflammation-induced phenoconversion. Medical Research Archives. https://doi.org/10.18103/mra.2026.0767
Vancouver
Clothier JL, Harville TO. Immune dysregulation and pharmacogenomics in neurodevelopmental disorders, part 2: a review of inflammation-induced phenoconversion. Medical Research Archives. 2026. doi:10.18103/mra.2026.0767
BibTeX
@article{Clothier2026,
author = {Clothier, Jeffrey L. and Harville, Terry O.},
title = {Immune dysregulation and pharmacogenomics in neurodevelopmental disorders, part 2: a review of inflammation-induced phenoconversion},
journal = {Medical Research Archives},
year = {2026},
doi = {10.18103/mra.2026.0767}
}
EUVIMED